Introduction

With the maturation of next generation sequencing platforms in clinical diagnostics the wealth of data that is generated in a time efficient and cost effective manner. On consequence of generation increased amounts of clinical data is the detection of incidental and/or unintended findings. A key consideration for many clinical labs is how to report or communicate these incidental findings to the ordering physician. Recently the ACMG has released a set of guidelines for reporting incidental findings; however, this article does not meet the needs of a genetics oncology laboratory on several fronts. Therefore, it is essential to identify and adopt a set of standards for reporting incidental findings detected in tumor samples that addresses the special needs of personalized medicine in oncology.